Adverum Biotechnologies - רווח לפני ריבית, מסים ופחת ADVM

Adverum Biotechnologies (ADVM) relies on stable demand in medicine, which makes it resilient to market crises. Operating income before taxes and depreciation reflects current dynamics, where 0.00 is recorded as the baseline value. Prospects are linked to the implementation of the one-time gene therapy Ixi-nanogene and the use of viral vectors in US centers to combat retinal pathologies.

To build a high-quality portfolio, I use this indicator as a tool to assess real cash flow from core operations before depreciation and taxes. The trend in EBITDA reflects the ability of Adverum Biotechnologies (ADVM) to monetize its unique Ixo-vec gene therapy, where strong pricing power in ophthalmology should translate into sustainable growth in operating revenues.